On September 3, 2026, smart-ring maker Oura publicly filed its S-1 registration statement, the required step toward an initial public offering, and disclosed $1.4 billion in revenue and $59 million in net income for the twelve-month period ended in June. Business Insider reported the company plans to list on the Nasdaq under the ticker OURA, and that revenue grew 74% year-over-year comparing the first three quarters of fiscal 2026 against the same period in 2025. Oura had 5 million paid members as of June.

Why It Matters

This is the first credible public-market comparable for a consumer device company whose growth story is explicitly a women's health story. Femtech has spent 2026 in a funding reset — SVB data put US women's health venture funding at roughly $2 billion in 2025, down from $3.2 billion in 2024 — and the category's exit narrative has been dominated by administrations, wind-downs and secondary-heavy rounds. An Oura listing at scale gives founders and investors something the sector has badly lacked: a real multiple to point at, on real revenue, in a business where the women's-health features are the retention engine rather than a marketing skin. It also puts intimate biometric data on a public-company disclosure schedule. Cycle, fertility, pregnancy and menopause signals collected continuously and processed through third-party frontier models are now subject to quarterly reporting, SEC risk-factor language and shareholder scrutiny — a materially different governance posture than a private company's privacy policy. For regulators worried about reproductive-health data post-Dobbs, and for the virtual-care partners now embedding Oura's instruments into clinical workflows, that visibility cuts both ways. The channel concentration deserves a flag too. A hardware business with two customers at 12% and 10% of revenue is exposed to retailer shelf decisions in exactly the way DTC sexual wellness and femtech brands have been complaining about all year. Oura's answer is subscription revenue and clinical distribution; the S-1 is effectively the argument that a ring is a wedge and the recurring health platform is the business.

The profitability picture is more complicated than the headline. The same filing shows losses of $924 million on revenue of $1.21 billion for the nine-month period ended in June, against losses of $182.8 million on revenue of $697.6 million in the prior-year period. Oura itself warns in the filing that it has "a history of operating losses" and has "only recently achieved profitability," adding that "there can be no assurance that we will maintain profitability in any future period." Reporting elsewhere has attributed the bulk of that nine-month loss to pre-IPO share buybacks from existing investors rather than operating burn — a distinction that matters, though the filing language is deliberately cautious either way.

What makes this an industry story rather than a wearables story is the composition of the customer base. Femtech Insider's read of the filing notes that women make up 72% of Oura's 5 million paid members, and that the company is expanding from sleep and cycle tracking into fertility, pregnancy, postpartum, perimenopause, menopause and healthy aging. Oura describes itself as building a "personal health system of record," combining biometric data with bloodwork, glucose data and health records, and has developed a proprietary AI-powered women's health coach to interpret longitudinal signals. Members have generated more than 42 billion hours of biometric data, and 33% of new members are first-time wearable buyers.

The clinical push is already underway and already covered on this beat: Oura's Menopause Impact Scale is being integrated into the workflows of virtual-care partners including Alloy and Maven, and the company is seeking a patent on a pregnancy-complication detection tool built on pulse-wave velocity. The S-1 turns those into disclosed strategy rather than product announcements.

The risk factors are worth reading for anyone modeling the sector. Oura flags tariffs and trade tensions as a cost pressure on hardware, concentration risk in its retail channel — its two largest customers accounted for 12% and 10% of revenue in the nine months ended June — and dependence on third-party AI models from OpenAI, Anthropic and Google plus third-party data centers, along with "legal, regulatory, ethical, security, or reputational risks" tied to AI. It also cautions that its rapid growth "may not be sustainable or indicative of future performance."

Sources

Update — 2026-09-08

{Initial entry — story first created.}